Summary

The global Radioactive Isotope Labeling Services market is projected to grow from US$ 311 million in 2025 to US$ 520 million by 2032, at a CAGR of 7.7% (2026-2032), driven by critical product segments and diverse end‑use applications.

Radioactive Isotope Labeling Services refer to specialized services that incorporate radioactive isotopes into drug candidates, active pharmaceutical ingredients, metabolites, agrochemicals, peptides, proteins, antibodies, nucleic acids, and other target molecules through radiosynthesis, isotope exchange, radioiodination, radiometal chelation, bioconjugation, and related radiochemical techniques. These services typically include labeling-site selection, synthetic route development, radiolabeling, purification, analytical characterization, quality control, formulation, and delivery according to research or clinical requirements. By providing target molecules with traceable radioactive signatures, these services support absorption, distribution, metabolism and excretion studies, mass balance studies, pharmacokinetic and tissue distribution studies, receptor and target research, agrochemical metabolism and environmental fate assessment, chemical safety evaluation, and radiopharmaceutical and molecular imaging development.

Key Findings
Carbon-14 labeling remains the principal service segment, supported by pharmaceutical ADME, human mass-balance and agrochemical metabolism studies
Small molecules remain the largest target class, while peptides, proteins, antibodies and oligonucleotides are creating new radiolabeling demand
Non-GMP services support the broader research project base, while GMP radiolabeling represents a higher-value and more compliance-intensive service category
North America and Europe remain the principal service hubs, while China is rapidly strengthening domestic radiochemistry and integrated ADME capabilities
Competition combines global CRO and CDMO platforms with highly specialized radiochemistry companies focused on individual isotopes, molecule classes or research applications

Market Trends
The Radioactive Isotope Labeling Services market is evolving from conventional small-molecule carbon-14 and tritium synthesis toward more technically demanding, integrated radiolabeled development programs. Customers increasingly expect service providers to support labeling-site strategy, radiosynthetic route design, purification, analytical characterization, storage, repurification and global shipment within a single project workflow. At the same time, the expansion of peptides, proteins, antibodies, antibody-drug conjugates, oligonucleotides and other new modalities is increasing demand for molecule-specific labeling technologies that preserve biological activity while achieving suitable radiochemical purity and specific activity. Pharmaron has extended carbon-14 and tritium labeling into proteins, peptides, antibodies, ADCs and oligonucleotides, while WuXi AppTec reports capabilities spanning small molecules, PROTACs, peptides, ADCs and oligonucleotides. Specialized suppliers are also upgrading analytical capabilities, including advanced NMR-based confirmation of tritium incorporation and increasingly integrated radioanalytical workflows. Another important trend is closer integration between radiosynthesis and downstream ADME, human mass-balance, QWBA, metabolite identification and clinical pharmacology programs, reducing handoffs between suppliers and increasing demand for end-to-end radiolabeled development platforms.

Market Dynamics
Drivers
Growth is primarily driven by the continued role of radiolabeled compounds in drug metabolism, pharmacokinetic and regulatory development programs. The FDA's final guidance on human radiolabeled mass-balance studies reinforces the importance of these studies in understanding the absorption, distribution, metabolism and excretion of investigational drugs, while OECD testing frameworks continue to require or favor radiolabeled active ingredients in important crop metabolism and environmental studies. Pharmaceutical outsourcing further supports demand because radioactive synthesis requires specialized licenses, radiation-controlled laboratories, experienced radiochemists and dedicated analytical infrastructure that many drug developers do not maintain internally. The growing complexity of development pipelines also increases the value of specialist partners capable of selecting metabolically stable labeling positions and managing radiochemical synthesis through final study delivery.

Restraints
Market expansion is constrained by the highly specialized nature of radiochemistry operations. Access to suitable radioactive starting materials and labeled intermediates is limited compared with conventional chemical synthesis, while radioactive waste treatment, occupational radiation protection, facility licensing and cross-border transportation add cost and operational complexity. Carbon-14 synthesis frequently requires route redesign around a limited set of commercially available radioactive building blocks, and high-specific-activity tritium synthesis requires specialized equipment and handling expertise. Project economics can also be challenging for very complex molecules because radioactive precursors are expensive, synthesis yields may decline over multiple steps and additional purification or repurification can be required as radiochemical purity changes during storage.

Opportunities
The strongest opportunities are emerging in new therapeutic modalities and higher-value integrated development services. Radiolabeling of peptides, antibodies, ADCs, proteins and oligonucleotides creates demand for specialized methods beyond conventional small-molecule synthesis, while clinical development generates opportunities for GMP carbon-14 APIs, investigational medicinal products and integrated synthesis-to-human-ADME programs. Expansion of domestic drug discovery and regulatory capabilities in China and other Asian markets is also supporting regional radiochemistry capacity, reducing historical dependence on European and North American suppliers. Providers able to combine radiosynthesis with metabolite identification, QWBA, clinical mass-balance studies, bioanalysis and regulatory documentation are positioned to capture a larger share of project value and build longer-term customer relationships.

Challenges
The central technical challenge is ensuring that incorporation of a radioactive isotope produces a tracer that accurately represents the behavior of the original molecule. Labeling positions must remain sufficiently stable during metabolism, while radioiodination or covalent modification of biologics must avoid materially altering binding affinity, biological function or disposition. Achieving the required combination of specific activity, radiochemical purity, chemical purity and stability becomes increasingly difficult for structurally complex molecules and macromolecules. Suppliers must also manage radionuclide decay, radiolytic degradation, storage conditions, regulatory documentation and international dangerous-goods logistics. For biologics in particular, the need to demonstrate that radiolabeling has preserved biological properties creates an additional analytical and assay burden compared with conventional small-molecule programs.

Industry Chain Analysis
The upstream portion of the industry chain consists of radioactive isotope raw materials and precursors, unlabeled starting materials and intermediates, specialized radiochemical reagents, analytical instruments, radiation-monitoring equipment and licensed radioactive-material logistics. Carbon-14 synthesis commonly relies on radioactive building blocks derived from carbon-14 feedstocks, while tritium programs use tritium gas, tritiated water and specialized tritiated reagents; radioiodine and other radionuclides support protein, peptide and specialized biologic labeling. The midstream service layer converts these inputs into customer-specific radiolabeled compounds through labeling-position assessment, radiosynthetic route development, synthesis, purification, analytical characterization, quality release, storage and shipment. Downstream customers primarily include pharmaceutical and biotechnology companies, agrochemical developers, life science researchers and research organizations conducting ADME, mass-balance, metabolism, receptor-binding and regulatory studies. Value creation is concentrated in radiochemistry expertise, successful route design, access to licensed facilities, analytical quality, GMP capability and the ability to integrate labeled compound supply directly into downstream studies.

Segment Insights
By isotope, Carbon-14 Labeling Services represent the largest and most broadly applicable segment. Carbon-14 can be incorporated at defined positions in the molecular structure and provides strong metabolic stability, making it particularly suitable for pharmaceutical ADME and human mass-balance studies as well as agrochemical metabolism, residue and environmental-fate programs. Tritium Labeling Services form another major segment and offer advantages where high molar activity is required, particularly in receptor-binding, pharmacology and drug-discovery applications. Radioiodine Labeling Services are more specialized and are widely associated with proteins, peptides, antibodies and radioligand research, while the Others category includes sulfur, phosphorus, radiometals and other radionuclides used for specific biochemical, molecular imaging or specialized research requirements.

By target molecule, Small Molecules continue to represent the largest commercial base because conventional pharmaceutical candidates and agrochemical active ingredients account for a large share of established radiolabeled ADME and metabolism studies. Peptides and Proteins, Antibodies and Bioconjugates, and Oligonucleotides and Nucleic Acids are becoming increasingly important as drug-development pipelines shift toward new modalities. From a regulatory and quality perspective, Non-GMP Radiolabeling Services account for the broader project base across discovery, preclinical and regulatory research, while GMP Radiolabeling Services carry higher technical and quality requirements and are concentrated in clinical-grade carbon-14 APIs and drug products. Dedicated GMP platforms operated by suppliers such as Pharmaron, Moravek, Almac, Nuvisan and Curachem illustrate the increasing commercial importance of this higher-value segment.

Downstream Market Opportunities
Pharmaceutical & Biotechnology represents the most important downstream opportunity, with radiolabeled compounds supporting discovery, nonclinical ADME, tissue distribution, metabolite identification, human mass-balance and clinical pharmacology programs. Agrochemical Development & Registration provides a comparatively mature but resilient demand base because radiolabeled active ingredients remain important for crop metabolism, residue, soil-water and environmental-fate studies. Life Science & Drug Discovery Research generates recurring demand for radioligands used in receptor-binding, target-engagement, transporter, enzyme and cellular studies, with tritium and radioiodine particularly relevant. Future growth opportunities are increasingly associated with complex therapeutic modalities and integrated outsourcing, as developers seek suppliers capable of moving a radiolabeled candidate from synthesis through analytical characterization and downstream biological or clinical studies without transferring the project between multiple vendors.

Regional Insights
North America and Europe constitute the principal global hubs for Radioactive Isotope Labeling Services, supported by large pharmaceutical and biotechnology R&D ecosystems and long-established specialist radiochemistry infrastructure. North America has a strong supplier base represented by Revvity, Labcorp, Moravek, American Radiolabeled Chemicals, ViTrax, AptoChem and AM Chemicals, while Europe contains a particularly dense network of specialist and integrated providers including Eurofins Scientific, Quotient Sciences, Almac Group, Nuvisan, Institute of Isotopes, Hartmann Analytic, Chelatec, RC Tritec and Novandi Chemistry. The European market also benefits from mature carbon-14, tritium and GMP radiochemistry expertise and established integration with pharmaceutical and agrochemical regulatory programs.

Asia is developing a broader domestic service base. China has established integrated radiolabeling capabilities through Pharmaron, WuXi AppTec, Frontage Laboratories, Medicilon and specialized suppliers including Zhejiang Isotope Labelled Compounds and Wuxi Beita Pharmatech. Japan remains an established market through Sekisui Medical's long-standing isotope synthesis and clinical pharmacokinetic capabilities, while South Korea has developed specialized carbon-14 capability through Curachem. This regional expansion is increasing local access to radioactive compound synthesis and supporting a gradual shift from imported radiolabeled material toward domestic and regional project execution.

Competitive Landscape Analysis
The competitive landscape combines diversified global CRO and CDMO platforms with highly specialized radiochemistry providers. Eurofins Scientific, Pharmaron, WuXi AppTec, Quotient Sciences, Revvity, Labcorp, Almac Group, Nuvisan and Sekisui Medical compete through broad development capabilities, global customer access and integration of radiosynthesis with analytical, ADME or clinical services. Specialized companies such as Moravek, Institute of Isotopes, American Radiolabeled Chemicals, Hartmann Analytic, Chelatec, ViTrax, RC Tritec, Novandi Chemistry, AptoChem, Curachem, PolyPeptide, AM Chemicals and Gifford Bioscience differentiate through isotope expertise, molecule-specific capabilities and flexible project execution. Chinese providers including Medicilon, Zhejiang Isotope Labelled Compounds, Wuxi Beita Pharmatech and Beijing North Institute of Biotechnology broaden regional supply. Competitive advantages are increasingly determined by radiochemist expertise, isotope and precursor access, successful labeling-site and route design, GMP and regulatory capabilities, radiochemical analytical depth, project turnaround time and secure international delivery.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Radioactive Isotope Labeling Services market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
Eurofins Scientific
Moravek
Quotient Sciences
Revvity
Labcorp
Almac Group
Nuvisan (ALS)
Sekisui Medical
Institute of Isotopes
Curachem
American Radiolabeled Chemicals
Hartmann Analytic
Chelatec
ViTrax
RC Tritec
Novandi Chemistry
AptoChem
PolyPeptide
AM Chemicals
Gifford Bioscience
Pharmaron
WuXi AppTec
Frontage Laboratories
Zhejiang Isotope Labelled Compounds
Medicilon
Wuxi Beita Pharmatech
Beijing North Institute of Biotechnology

Segment by Type
Carbon-14 Labeling Services
Tritium Labeling Services
Radioiodine Labeling Services
Others

Segment by Target Molecule
Small Molecules
Peptides and Proteins
Antibodies and Bioconjugates
Oligonucleotides and Nucleic Acids
Others

Segment by Regulatory and Quality Level
Non-GMP Radiolabeling Services
GMP Radiolabeling Services

Segment by Application
Pharmaceutical & Biotechnology
Agrochemical Development & Registration
Life Science & Drug Discovery Research
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Radioactive Isotope Labeling Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Radioactive Isotope Labeling Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Radioactive Isotope Labeling Services Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Carbon-14 Labeling Services
1.2.3 Tritium Labeling Services
1.2.4 Radioiodine Labeling Services
1.2.5 Others
1.3 Market Segmentation by Target Molecule
1.3.1 Global Radioactive Isotope Labeling Services Market Size by Target Molecule, 2021 vs 2025 vs 2032
1.3.2 Small Molecules
1.3.3 Peptides and Proteins
1.3.4 Antibodies and Bioconjugates
1.3.5 Oligonucleotides and Nucleic Acids
1.3.6 Others
1.4 Market Segmentation by Regulatory and Quality Level
1.4.1 Global Radioactive Isotope Labeling Services Market Size by Regulatory and Quality Level, 2021 vs 2025 vs 2032
1.4.2 Non-GMP Radiolabeling Services
1.4.3 GMP Radiolabeling Services
1.5 Market Segmentation by Application
1.5.1 Global Radioactive Isotope Labeling Services Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical & Biotechnology
1.5.3 Agrochemical Development & Registration
1.5.4 Life Science & Drug Discovery Research
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Radioactive Isotope Labeling Services Revenue Estimates and Forecasts (2021-2032)
2.2 Global Radioactive Isotope Labeling Services Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Radioactive Isotope Labeling Services Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Radioactive Isotope Labeling Services Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Carbon-14 Labeling Services: Market Share by Key Players
3.3.2 Tritium Labeling Services: Market Share by Key Players
3.3.3 Radioiodine Labeling Services: Market Share by Key Players
3.3.4 Others: Market Share by Key Players
3.4 Global Radioactive Isotope Labeling Services Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Radioactive Isotope Labeling Services Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Radioactive Isotope Labeling Services Market by Target Molecule
4.2.1 Global Revenue by Target Molecule (2021-2032)
4.2.2 Global Revenue-Based Market Share by Target Molecule (2021-2032)
4.3 Global Radioactive Isotope Labeling Services Market by Regulatory and Quality Level
4.3.1 Global Revenue by Regulatory and Quality Level (2021-2032)
4.3.2 Global Revenue-Based Market Share by Regulatory and Quality Level (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Radioactive Isotope Labeling Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Radioactive Isotope Labeling Services Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Radioactive Isotope Labeling Services Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Radioactive Isotope Labeling Services Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Radioactive Isotope Labeling Services Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Radioactive Isotope Labeling Services Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Radioactive Isotope Labeling Services Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Radioactive Isotope Labeling Services Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Radioactive Isotope Labeling Services Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Radioactive Isotope Labeling Services Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Radioactive Isotope Labeling Services Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Eurofins Scientific
11.1.1 Eurofins Scientific Corporation Information
11.1.2 Eurofins Scientific Business Overview
11.1.3 Eurofins Scientific Radioactive Isotope Labeling Services Product Features and Attributes
11.1.4 Eurofins Scientific Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.1.5 Eurofins Scientific Radioactive Isotope Labeling Services Revenue by Product in 2025
11.1.6 Eurofins Scientific Radioactive Isotope Labeling Services Revenue by Application in 2025
11.1.7 Eurofins Scientific Radioactive Isotope Labeling Services Revenue by Geographic Area in 2025
11.1.8 Eurofins Scientific Radioactive Isotope Labeling Services SWOT Analysis
11.1.9 Eurofins Scientific Recent Developments
11.2 Moravek
11.2.1 Moravek Corporation Information
11.2.2 Moravek Business Overview
11.2.3 Moravek Radioactive Isotope Labeling Services Product Features and Attributes
11.2.4 Moravek Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.2.5 Moravek Radioactive Isotope Labeling Services Revenue by Product in 2025
11.2.6 Moravek Radioactive Isotope Labeling Services Revenue by Application in 2025
11.2.7 Moravek Radioactive Isotope Labeling Services Revenue by Geographic Area in 2025
11.2.8 Moravek Radioactive Isotope Labeling Services SWOT Analysis
11.2.9 Moravek Recent Developments
11.3 Quotient Sciences
11.3.1 Quotient Sciences Corporation Information
11.3.2 Quotient Sciences Business Overview
11.3.3 Quotient Sciences Radioactive Isotope Labeling Services Product Features and Attributes
11.3.4 Quotient Sciences Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.3.5 Quotient Sciences Radioactive Isotope Labeling Services Revenue by Product in 2025
11.3.6 Quotient Sciences Radioactive Isotope Labeling Services Revenue by Application in 2025
11.3.7 Quotient Sciences Radioactive Isotope Labeling Services Revenue by Geographic Area in 2025
11.3.8 Quotient Sciences Radioactive Isotope Labeling Services SWOT Analysis
11.3.9 Quotient Sciences Recent Developments
11.4 Revvity
11.4.1 Revvity Corporation Information
11.4.2 Revvity Business Overview
11.4.3 Revvity Radioactive Isotope Labeling Services Product Features and Attributes
11.4.4 Revvity Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.4.5 Revvity Radioactive Isotope Labeling Services Revenue by Product in 2025
11.4.6 Revvity Radioactive Isotope Labeling Services Revenue by Application in 2025
11.4.7 Revvity Radioactive Isotope Labeling Services Revenue by Geographic Area in 2025
11.4.8 Revvity Radioactive Isotope Labeling Services SWOT Analysis
11.4.9 Revvity Recent Developments
11.5 Labcorp
11.5.1 Labcorp Corporation Information
11.5.2 Labcorp Business Overview
11.5.3 Labcorp Radioactive Isotope Labeling Services Product Features and Attributes
11.5.4 Labcorp Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.5.5 Labcorp Radioactive Isotope Labeling Services Revenue by Product in 2025
11.5.6 Labcorp Radioactive Isotope Labeling Services Revenue by Application in 2025
11.5.7 Labcorp Radioactive Isotope Labeling Services Revenue by Geographic Area in 2025
11.5.8 Labcorp Radioactive Isotope Labeling Services SWOT Analysis
11.5.9 Labcorp Recent Developments
11.6 Almac Group
11.6.1 Almac Group Corporation Information
11.6.2 Almac Group Business Overview
11.6.3 Almac Group Radioactive Isotope Labeling Services Product Features and Attributes
11.6.4 Almac Group Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.6.5 Almac Group Recent Developments
11.7 Nuvisan (ALS)
11.7.1 Nuvisan (ALS) Corporation Information
11.7.2 Nuvisan (ALS) Business Overview
11.7.3 Nuvisan (ALS) Radioactive Isotope Labeling Services Product Features and Attributes
11.7.4 Nuvisan (ALS) Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.7.5 Nuvisan (ALS) Recent Developments
11.8 Sekisui Medical
11.8.1 Sekisui Medical Corporation Information
11.8.2 Sekisui Medical Business Overview
11.8.3 Sekisui Medical Radioactive Isotope Labeling Services Product Features and Attributes
11.8.4 Sekisui Medical Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.8.5 Sekisui Medical Recent Developments
11.9 Institute of Isotopes
11.9.1 Institute of Isotopes Corporation Information
11.9.2 Institute of Isotopes Business Overview
11.9.3 Institute of Isotopes Radioactive Isotope Labeling Services Product Features and Attributes
11.9.4 Institute of Isotopes Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.9.5 Institute of Isotopes Recent Developments
11.10 Curachem
11.10.1 Curachem Corporation Information
11.10.2 Curachem Business Overview
11.10.3 Curachem Radioactive Isotope Labeling Services Product Features and Attributes
11.10.4 Curachem Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 American Radiolabeled Chemicals
11.11.1 American Radiolabeled Chemicals Corporation Information
11.11.2 American Radiolabeled Chemicals Business Overview
11.11.3 American Radiolabeled Chemicals Radioactive Isotope Labeling Services Product Features and Attributes
11.11.4 American Radiolabeled Chemicals Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.11.5 American Radiolabeled Chemicals Recent Developments
11.12 Hartmann Analytic
11.12.1 Hartmann Analytic Corporation Information
11.12.2 Hartmann Analytic Business Overview
11.12.3 Hartmann Analytic Radioactive Isotope Labeling Services Product Features and Attributes
11.12.4 Hartmann Analytic Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.12.5 Hartmann Analytic Recent Developments
11.13 Chelatec
11.13.1 Chelatec Corporation Information
11.13.2 Chelatec Business Overview
11.13.3 Chelatec Radioactive Isotope Labeling Services Product Features and Attributes
11.13.4 Chelatec Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.13.5 Chelatec Recent Developments
11.14 ViTrax
11.14.1 ViTrax Corporation Information
11.14.2 ViTrax Business Overview
11.14.3 ViTrax Radioactive Isotope Labeling Services Product Features and Attributes
11.14.4 ViTrax Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.14.5 ViTrax Recent Developments
11.15 RC Tritec
11.15.1 RC Tritec Corporation Information
11.15.2 RC Tritec Business Overview
11.15.3 RC Tritec Radioactive Isotope Labeling Services Product Features and Attributes
11.15.4 RC Tritec Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.15.5 RC Tritec Recent Developments
11.16 Novandi Chemistry
11.16.1 Novandi Chemistry Corporation Information
11.16.2 Novandi Chemistry Business Overview
11.16.3 Novandi Chemistry Radioactive Isotope Labeling Services Product Features and Attributes
11.16.4 Novandi Chemistry Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.16.5 Novandi Chemistry Recent Developments
11.17 AptoChem
11.17.1 AptoChem Corporation Information
11.17.2 AptoChem Business Overview
11.17.3 AptoChem Radioactive Isotope Labeling Services Product Features and Attributes
11.17.4 AptoChem Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.17.5 AptoChem Recent Developments
11.18 PolyPeptide
11.18.1 PolyPeptide Corporation Information
11.18.2 PolyPeptide Business Overview
11.18.3 PolyPeptide Radioactive Isotope Labeling Services Product Features and Attributes
11.18.4 PolyPeptide Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.18.5 PolyPeptide Recent Developments
11.19 AM Chemicals
11.19.1 AM Chemicals Corporation Information
11.19.2 AM Chemicals Business Overview
11.19.3 AM Chemicals Radioactive Isotope Labeling Services Product Features and Attributes
11.19.4 AM Chemicals Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.19.5 AM Chemicals Recent Developments
11.20 Gifford Bioscience
11.20.1 Gifford Bioscience Corporation Information
11.20.2 Gifford Bioscience Business Overview
11.20.3 Gifford Bioscience Radioactive Isotope Labeling Services Product Features and Attributes
11.20.4 Gifford Bioscience Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.20.5 Gifford Bioscience Recent Developments
11.21 Pharmaron
11.21.1 Pharmaron Corporation Information
11.21.2 Pharmaron Business Overview
11.21.3 Pharmaron Radioactive Isotope Labeling Services Product Features and Attributes
11.21.4 Pharmaron Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.21.5 Pharmaron Recent Developments
11.22 WuXi AppTec
11.22.1 WuXi AppTec Corporation Information
11.22.2 WuXi AppTec Business Overview
11.22.3 WuXi AppTec Radioactive Isotope Labeling Services Product Features and Attributes
11.22.4 WuXi AppTec Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.22.5 WuXi AppTec Recent Developments
11.23 Frontage Laboratories
11.23.1 Frontage Laboratories Corporation Information
11.23.2 Frontage Laboratories Business Overview
11.23.3 Frontage Laboratories Radioactive Isotope Labeling Services Product Features and Attributes
11.23.4 Frontage Laboratories Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.23.5 Frontage Laboratories Recent Developments
11.24 Zhejiang Isotope Labelled Compounds
11.24.1 Zhejiang Isotope Labelled Compounds Corporation Information
11.24.2 Zhejiang Isotope Labelled Compounds Business Overview
11.24.3 Zhejiang Isotope Labelled Compounds Radioactive Isotope Labeling Services Product Features and Attributes
11.24.4 Zhejiang Isotope Labelled Compounds Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.24.5 Zhejiang Isotope Labelled Compounds Recent Developments
11.25 Medicilon
11.25.1 Medicilon Corporation Information
11.25.2 Medicilon Business Overview
11.25.3 Medicilon Radioactive Isotope Labeling Services Product Features and Attributes
11.25.4 Medicilon Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.25.5 Medicilon Recent Developments
11.26 Wuxi Beita Pharmatech
11.26.1 Wuxi Beita Pharmatech Corporation Information
11.26.2 Wuxi Beita Pharmatech Business Overview
11.26.3 Wuxi Beita Pharmatech Radioactive Isotope Labeling Services Product Features and Attributes
11.26.4 Wuxi Beita Pharmatech Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.26.5 Wuxi Beita Pharmatech Recent Developments
11.27 Beijing North Institute of Biotechnology
11.27.1 Beijing North Institute of Biotechnology Corporation Information
11.27.2 Beijing North Institute of Biotechnology Business Overview
11.27.3 Beijing North Institute of Biotechnology Radioactive Isotope Labeling Services Product Features and Attributes
11.27.4 Beijing North Institute of Biotechnology Radioactive Isotope Labeling Services Revenue and Gross Margin (2021-2026)
11.27.5 Beijing North Institute of Biotechnology Recent Developments

12 Radioactive Isotope Labeling Services Value Chain and Ecosystem Analysis
12.1 Radioactive Isotope Labeling Services Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Radioactive Isotope Labeling Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Radioactive Isotope Labeling Services Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Radioactive Isotope Labeling Services Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Radioactive Isotope Labeling Services Market Size Growth Rate by Target Molecule, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Radioactive Isotope Labeling Services Market Size Growth Rate by Regulatory and Quality Level, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Radioactive Isotope Labeling Services Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Radioactive Isotope Labeling Services Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Radioactive Isotope Labeling Services Revenue by Region (US$ Million), 2021-2026
Table 7. Global Radioactive Isotope Labeling Services Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Radioactive Isotope Labeling Services Revenue by Players (US$ Million), 2021-2026
Table 10. Global Radioactive Isotope Labeling Services Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Radioactive Isotope Labeling Services Revenue, 2025
Table 13. Global Radioactive Isotope Labeling Services Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Radioactive Isotope Labeling Services Companies Headquarters
Table 15. Global Radioactive Isotope Labeling Services Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Radioactive Isotope Labeling Services Revenue by Type (US$ Million), 2021-2026
Table 19. Global Radioactive Isotope Labeling Services Revenue by Type (US$ Million), 2027-2032
Table 20. Global Radioactive Isotope Labeling Services Revenue by Target Molecule (US$ Million), 2021-2026
Table 21. Global Radioactive Isotope Labeling Services Revenue by Target Molecule (US$ Million), 2027-2032
Table 22. Global Radioactive Isotope Labeling Services Revenue by Regulatory and Quality Level (US$ Million), 2021-2026
Table 23. Global Radioactive Isotope Labeling Services Revenue by Regulatory and Quality Level (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Radioactive Isotope Labeling Services Revenue by Application (US$ Million), 2021-2026
Table 26. Global Radioactive Isotope Labeling Services Revenue by Application (US$ Million), 2027-2032
Table 27. Radioactive Isotope Labeling Services High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Radioactive Isotope Labeling Services Growth Accelerators and Market Barriers
Table 31. North America Radioactive Isotope Labeling Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Radioactive Isotope Labeling Services Growth Accelerators and Market Barriers
Table 33. Europe Radioactive Isotope Labeling Services Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Radioactive Isotope Labeling Services Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Radioactive Isotope Labeling Services Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Radioactive Isotope Labeling Services Investment Opportunities and Key Challenges
Table 37. Central and South America Radioactive Isotope Labeling Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Radioactive Isotope Labeling Services Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Radioactive Isotope Labeling Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Eurofins Scientific Corporation Information
Table 41. Eurofins Scientific Description and Major Businesses
Table 42. Eurofins Scientific Product Features and Attributes
Table 43. Eurofins Scientific Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Eurofins Scientific Revenue Proportion by Product in 2025
Table 45. Eurofins Scientific Revenue Proportion by Application in 2025
Table 46. Eurofins Scientific Revenue Proportion by Geographic Area in 2025
Table 47. Eurofins Scientific Radioactive Isotope Labeling Services SWOT Analysis
Table 48. Eurofins Scientific Recent Developments
Table 49. Moravek Corporation Information
Table 50. Moravek Description and Major Businesses
Table 51. Moravek Product Features and Attributes
Table 52. Moravek Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Moravek Revenue Proportion by Product in 2025
Table 54. Moravek Revenue Proportion by Application in 2025
Table 55. Moravek Revenue Proportion by Geographic Area in 2025
Table 56. Moravek Radioactive Isotope Labeling Services SWOT Analysis
Table 57. Moravek Recent Developments
Table 58. Quotient Sciences Corporation Information
Table 59. Quotient Sciences Description and Major Businesses
Table 60. Quotient Sciences Product Features and Attributes
Table 61. Quotient Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Quotient Sciences Revenue Proportion by Product in 2025
Table 63. Quotient Sciences Revenue Proportion by Application in 2025
Table 64. Quotient Sciences Revenue Proportion by Geographic Area in 2025
Table 65. Quotient Sciences Radioactive Isotope Labeling Services SWOT Analysis
Table 66. Quotient Sciences Recent Developments
Table 67. Revvity Corporation Information
Table 68. Revvity Description and Major Businesses
Table 69. Revvity Product Features and Attributes
Table 70. Revvity Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Revvity Revenue Proportion by Product in 2025
Table 72. Revvity Revenue Proportion by Application in 2025
Table 73. Revvity Revenue Proportion by Geographic Area in 2025
Table 74. Revvity Radioactive Isotope Labeling Services SWOT Analysis
Table 75. Revvity Recent Developments
Table 76. Labcorp Corporation Information
Table 77. Labcorp Description and Major Businesses
Table 78. Labcorp Product Features and Attributes
Table 79. Labcorp Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Labcorp Revenue Proportion by Product in 2025
Table 81. Labcorp Revenue Proportion by Application in 2025
Table 82. Labcorp Revenue Proportion by Geographic Area in 2025
Table 83. Labcorp Radioactive Isotope Labeling Services SWOT Analysis
Table 84. Labcorp Recent Developments
Table 85. Almac Group Corporation Information
Table 86. Almac Group Description and Major Businesses
Table 87. Almac Group Product Features and Attributes
Table 88. Almac Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Almac Group Recent Developments
Table 90. Nuvisan (ALS) Corporation Information
Table 91. Nuvisan (ALS) Description and Major Businesses
Table 92. Nuvisan (ALS) Product Features and Attributes
Table 93. Nuvisan (ALS) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Nuvisan (ALS) Recent Developments
Table 95. Sekisui Medical Corporation Information
Table 96. Sekisui Medical Description and Major Businesses
Table 97. Sekisui Medical Product Features and Attributes
Table 98. Sekisui Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Sekisui Medical Recent Developments
Table 100. Institute of Isotopes Corporation Information
Table 101. Institute of Isotopes Description and Major Businesses
Table 102. Institute of Isotopes Product Features and Attributes
Table 103. Institute of Isotopes Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Institute of Isotopes Recent Developments
Table 105. Curachem Corporation Information
Table 106. Curachem Description and Major Businesses
Table 107. Curachem Product Features and Attributes
Table 108. Curachem Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Curachem Recent Developments
Table 110. American Radiolabeled Chemicals Corporation Information
Table 111. American Radiolabeled Chemicals Description and Major Businesses
Table 112. American Radiolabeled Chemicals Product Features and Attributes
Table 113. American Radiolabeled Chemicals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. American Radiolabeled Chemicals Recent Developments
Table 115. Hartmann Analytic Corporation Information
Table 116. Hartmann Analytic Description and Major Businesses
Table 117. Hartmann Analytic Product Features and Attributes
Table 118. Hartmann Analytic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hartmann Analytic Recent Developments
Table 120. Chelatec Corporation Information
Table 121. Chelatec Description and Major Businesses
Table 122. Chelatec Product Features and Attributes
Table 123. Chelatec Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Chelatec Recent Developments
Table 125. ViTrax Corporation Information
Table 126. ViTrax Description and Major Businesses
Table 127. ViTrax Product Features and Attributes
Table 128. ViTrax Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. ViTrax Recent Developments
Table 130. RC Tritec Corporation Information
Table 131. RC Tritec Description and Major Businesses
Table 132. RC Tritec Product Features and Attributes
Table 133. RC Tritec Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. RC Tritec Recent Developments
Table 135. Novandi Chemistry Corporation Information
Table 136. Novandi Chemistry Description and Major Businesses
Table 137. Novandi Chemistry Product Features and Attributes
Table 138. Novandi Chemistry Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Novandi Chemistry Recent Developments
Table 140. AptoChem Corporation Information
Table 141. AptoChem Description and Major Businesses
Table 142. AptoChem Product Features and Attributes
Table 143. AptoChem Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. AptoChem Recent Developments
Table 145. PolyPeptide Corporation Information
Table 146. PolyPeptide Description and Major Businesses
Table 147. PolyPeptide Product Features and Attributes
Table 148. PolyPeptide Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. PolyPeptide Recent Developments
Table 150. AM Chemicals Corporation Information
Table 151. AM Chemicals Description and Major Businesses
Table 152. AM Chemicals Product Features and Attributes
Table 153. AM Chemicals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. AM Chemicals Recent Developments
Table 155. Gifford Bioscience Corporation Information
Table 156. Gifford Bioscience Description and Major Businesses
Table 157. Gifford Bioscience Product Features and Attributes
Table 158. Gifford Bioscience Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Gifford Bioscience Recent Developments
Table 160. Pharmaron Corporation Information
Table 161. Pharmaron Description and Major Businesses
Table 162. Pharmaron Product Features and Attributes
Table 163. Pharmaron Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Pharmaron Recent Developments
Table 165. WuXi AppTec Corporation Information
Table 166. WuXi AppTec Description and Major Businesses
Table 167. WuXi AppTec Product Features and Attributes
Table 168. WuXi AppTec Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. WuXi AppTec Recent Developments
Table 170. Frontage Laboratories Corporation Information
Table 171. Frontage Laboratories Description and Major Businesses
Table 172. Frontage Laboratories Product Features and Attributes
Table 173. Frontage Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Frontage Laboratories Recent Developments
Table 175. Zhejiang Isotope Labelled Compounds Corporation Information
Table 176. Zhejiang Isotope Labelled Compounds Description and Major Businesses
Table 177. Zhejiang Isotope Labelled Compounds Product Features and Attributes
Table 178. Zhejiang Isotope Labelled Compounds Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Zhejiang Isotope Labelled Compounds Recent Developments
Table 180. Medicilon Corporation Information
Table 181. Medicilon Description and Major Businesses
Table 182. Medicilon Product Features and Attributes
Table 183. Medicilon Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Medicilon Recent Developments
Table 185. Wuxi Beita Pharmatech Corporation Information
Table 186. Wuxi Beita Pharmatech Description and Major Businesses
Table 187. Wuxi Beita Pharmatech Product Features and Attributes
Table 188. Wuxi Beita Pharmatech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. Wuxi Beita Pharmatech Recent Developments
Table 190. Beijing North Institute of Biotechnology Corporation Information
Table 191. Beijing North Institute of Biotechnology Description and Major Businesses
Table 192. Beijing North Institute of Biotechnology Product Features and Attributes
Table 193. Beijing North Institute of Biotechnology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Beijing North Institute of Biotechnology Recent Developments
Table 195. Technologies, Platforms and Infrastructure
Table 196. Distributors List
Table 197. Market Trends and Market Evolution
Table 198. Market Drivers and Opportunities
Table 199. Market Challenges, Risks, and Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Radioactive Isotope Labeling Services Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Carbon-14 Labeling Services Product Picture
Figure 3. Tritium Labeling Services Product Picture
Figure 4. Radioiodine Labeling Services Product Picture
Figure 5. Others Product Picture
Figure 6. Global Radioactive Isotope Labeling Services Market Size Growth Rate by Target Molecule, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Small Molecules Product Picture
Figure 8. Peptides and Proteins Product Picture
Figure 9. Antibodies and Bioconjugates Product Picture
Figure 10. Oligonucleotides and Nucleic Acids Product Picture
Figure 11. Others Product Picture
Figure 12. Global Radioactive Isotope Labeling Services Market Size Growth Rate by Regulatory and Quality Level, 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. Non-GMP Radiolabeling Services Product Picture
Figure 14. GMP Radiolabeling Services Product Picture
Figure 15. Global Radioactive Isotope Labeling Services Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Pharmaceutical & Biotechnology
Figure 17. Agrochemical Development & Registration
Figure 18. Life Science & Drug Discovery Research
Figure 19. Others
Figure 20. Radioactive Isotope Labeling Services Report Years Considered
Figure 21. Global Radioactive Isotope Labeling Services Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 23. Global Radioactive Isotope Labeling Services Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 24. Global Radioactive Isotope Labeling Services Revenue-Based Market Share by Region (2021-2032)
Figure 25. Global Radioactive Isotope Labeling Services Revenue-Based Market Share Ranking (2025)
Figure 26. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 27. Carbon-14 Labeling Services Revenue-Based Market Share by Player in 2025
Figure 28. Tritium Labeling Services Revenue-Based Market Share by Player in 2025
Figure 29. Radioiodine Labeling Services Revenue-Based Market Share by Player in 2025
Figure 30. Others Revenue-Based Market Share by Player in 2025
Figure 31. Global Radioactive Isotope Labeling Services Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Radioactive Isotope Labeling Services Revenue-Based Market Share by Target Molecule (2021-2032)
Figure 33. Global Radioactive Isotope Labeling Services Revenue-Based Market Share by Regulatory and Quality Level (2021-2032)
Figure 34. Global Radioactive Isotope Labeling Services Revenue-Based Market Share by Application (2021-2032)
Figure 35. North America Radioactive Isotope Labeling Services Revenue YoY (US$ Million), 2021-2032
Figure 36. North America Top 5 Players Radioactive Isotope Labeling Services Revenue (US$ Million) in 2025
Figure 37. North America Radioactive Isotope Labeling Services Revenue (US$ Million) by Application (2021-2032)
Figure 38. US Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 39. Canada Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 40. Mexico Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 41. Europe Radioactive Isotope Labeling Services Revenue YoY (US$ Million), 2021-2032
Figure 42. Europe Top 5 Players Radioactive Isotope Labeling Services Revenue (US$ Million) in 2025
Figure 43. Europe Radioactive Isotope Labeling Services Revenue (US$ Million) by Application (2021-2032)
Figure 44. Germany Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 45. France Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 46. U.K. Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 47. Italy Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 48. Russia Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 49. Asia-Pacific Radioactive Isotope Labeling Services Revenue YoY (US$ Million), 2021-2032
Figure 50. Asia-Pacific Top 8 Players Radioactive Isotope Labeling Services Revenue (US$ Million) in 2025
Figure 51. Asia-Pacific Radioactive Isotope Labeling Services Revenue (US$ Million) by Application (2021-2032)
Figure 52. Indonesia Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 53. Japan Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 54. South Korea Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 55. Australia Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 56. India Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 57. Indonesia Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 58. Vietnam Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 59. Malaysia Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 60. Philippines Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 61. Singapore Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 62. Central and South America Radioactive Isotope Labeling Services Revenue YoY (US$ Million), 2021-2032
Figure 63. Central and South America Top 5 Players Radioactive Isotope Labeling Services Revenue (US$ Million) in 2025
Figure 64. Central and South America Radioactive Isotope Labeling Services Revenue (US$ Million) by Application (2021-2032)
Figure 65. Brazil Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 66. Argentina Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 67. Middle East and Africa Radioactive Isotope Labeling Services Revenue YoY (US$ Million), 2021-2032
Figure 68. Middle East and Africa Top 5 Players Radioactive Isotope Labeling Services Revenue (US$ Million) in 2025
Figure 69. Middle East and Africa Radioactive Isotope Labeling Services Revenue (US$ Million) by Application (2021-2032)
Figure 70. GCC Countries Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 71. Israel Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 72. Egypt Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 73. South Africa Radioactive Isotope Labeling Services Revenue (US$ Million), 2021-2032
Figure 74. Radioactive Isotope Labeling Services Value Chain Mapping
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed